Trial reportJournal of ovarian research2026
Overall survival and long-term safety of olaparib maintenance in patients with platinum-sensitive relapsed ovarian cancer: final analyses of phase III L-MOCA trial.
Trial report in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
backgroundThe indications for Poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy in platinum-sensitive recurrent ovarian cancer (PSROC) patients varies across nations. The lack of clinical trial evidence and detailed biomarker analysis in the Asian population results in uncertain clinical benefits. Additionally, the absence of long-term safety monitoring data limits the assessment of tolerance to prolonged PARP inhibitor use.
methodsThis prospective, open-label, single-arm, phase IIIb L-MOCA study enrolled Asian patients with high-grade epithelial PSROC across China and Malaysia. Patients received oral olaparib (300 mg) twice daily until disease progression or unacceptable toxicity. The primary endpoint of progression-free survival has been reported previously. A prespecified final OS analysis was conducted at approximately 60% data maturity.
resultsAfter a median follow-up of 73.4 months, the median OS (mOS) reached 51.0 months (95% CI, 42.7 to 56.1). The mOS was 64.4 months (49.9 to not reach [NR]) in BRCA-mutated patients and 40.9 months (33.3 to 51.0) in BRCA wild-type patients. The mOS was 54.4 months (42.5 to NE) in HRD-positive patients and 34.8 months (28.3 to 46.6) in HRD-negative patients. No new safety signals were identified compared to the primary L-MOCA report. Myelodysplastic syndrome and acute myeloid leukemia (MDS/AML) occurred in 1.3% of patients, and no additional cases were identified after approximately four additional years of follow-up beyond the primary analysis.
conclusionLong-term follow-up data from L-MOCA indicates that olaparib maintenance monotherapy shows promising overall survival and tolerable safety profile in Asian PSROC patients, regardless of BRCA or HRD status.
trial registrationRegistry: ClinicalTrials.gov.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.